Lunit Supplies AI to Major US Healthcare Group, Expanding Reach to 330+ Institutions

In a significant stride for medical innovation, South Korean AI firm Lunit has announced a major expansion of its reach in the Americas. The company's integrated breast cancer AI diagnostic solution has been deployed at Lexington Clinic, the largest healthcare group in central Kentucky. This collaboration marks a pivotal moment, showcasing the growing trust and adoption of advanced AI technologies in mainstream healthcare settings across the region.

“

Our goal is to provide the highest level of care while maintaining workflow efficiency and consistency. With the introduction of Lunit products, we can achieve more certain and faster decision-making for all patients by integrating risk prediction, detection, and quality management into one platform.

Lunit's success is built on its comprehensive platform, which includes 'Lunit Insight MMG' for mammography analysis and 'Lunit Insight DBT' for 3D mammography, alongside affiliated solutions for image quality optimization and patient management. The integration of these tools aims to streamline the entire breast cancer diagnosis process, offering healthcare providers a unified system for more accurate and efficient decision-making. This holistic approach is particularly valued by institutions like Lexington Clinic, which prioritize delivering top-tier care while maintaining workflow efficiency.

“

The spread from pilot adoption to entire medical institutions in the Americas is clearly evident. This means that AI is proving its practical value in everyday clinical practice.

The expansion to over 330 medical institutions in the Americas within a year of launching its integrated solution underscores Lunit's potent combination of technological prowess and market penetration. As Craig Hadfield, CEO of Lunit International, noted, this widespread adoption signifies that AI is proving its tangible value in everyday clinical practice. For Lunit, this isn't just about business growth; it's about demonstrating the real-world impact of their AI in improving patient outcomes and supporting medical professionals. The company's commitment to refining its products, evidenced by recent FDA approvals for upgraded features, signals a sustained effort to lead in the global fight against breast cancer.

“

Supplying an integrated solution covering the entire breast cancer screening process to a major US medical group and expanding our business to over 330 locations in the Americas is a result of the combined strengths of Lunit's AI technology and Lunit International's market capabilities. We will continue to expand our influence in the global breast cancer screening market beyond the Americas.